Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients ; day:7 ; month:8 ; year:2023 ; pages:1-10
European radiology ; (7.8.2023), 1-10
- Creator
-
Klimeš, Filip
Voskrebenzev, Andreas
Gutberlet, Marcel
Speth, Milan
Grimm, Robert
Dohna, Martha
Hansen, Gesine
Wacker, Frank
Renz, Diane Miriam
Dittrich, Anna-Maria
Vogel-Claussen, Jens
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00330-023-09912-6
- URN
-
urn:nbn:de:101:1-2023110208141283825503
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Klimeš, Filip
- Voskrebenzev, Andreas
- Gutberlet, Marcel
- Speth, Milan
- Grimm, Robert
- Dohna, Martha
- Hansen, Gesine
- Wacker, Frank
- Renz, Diane Miriam
- Dittrich, Anna-Maria
- Vogel-Claussen, Jens
- SpringerLink (Online service)
Other Objects (12)
CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis
Charakterisierung von inflammatorischen und infektiologischen Biomarkern von Kindern mit zystischer Fibrose unter neu begonnener CFTR-Modulator (Lumacaftor/ Ivacaftor) Therapie
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis
Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment
The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Targeted therapies to improve CFTR function in cystic fibrosis
CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis
Charakterisierung von inflammatorischen und infektiologischen Biomarkern von Kindern mit zystischer Fibrose unter neu begonnener CFTR-Modulator (Lumacaftor/ Ivacaftor) Therapie
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis
Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment
The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
Targeted therapies to improve CFTR function in cystic fibrosis
CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis
Charakterisierung von inflammatorischen und infektiologischen Biomarkern von Kindern mit zystischer Fibrose unter neu begonnener CFTR-Modulator (Lumacaftor/ Ivacaftor) Therapie
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis
Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment
The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor